This student paper was written as an assignment in the graduate course

*Free Radicals in Biology and Medicine*

(77:222, Spring 2003)

offered by the

Free Radical and Radiation Biology Program
B-180 Med Labs
The University of Iowa
Iowa City, IA  52242-1181
Spring 2003 Term

Instructors:
GARRY R. BUETTNER, Ph.D.
LARRY W. OBERLEY, Ph.D.

with guest lectures from:
Drs. Freya Q. Schafer, Douglas R. Spitz, and Frederick E. Domann

The Fine Print:

Because this is a paper written by a beginning student as an assignment, there are no guarantees that everything is absolutely correct and accurate.

In view of the possibility of human error or changes in our knowledge due to continued research, neither the author nor The University of Iowa nor any other party who has been involved in the preparation or publication of this work warrants that the information contained herein is in every respect accurate or complete, and they are not responsible for any errors or omissions or for the results obtained from the use of such information. Readers are encouraged to confirm the information contained herein with other sources.

All material contained in this paper is copyright of the author, or the owner of the source that the material was taken from. This work is not intended as a threat to the ownership of said copyrights.
Endothelial Nitric Oxide Synthase

by

Roman N Rodionov

3150ML

Department of Internal Medicine

The University of Iowa

Iowa City, IA 52242

For 77:222 Spring 2003

03.13.03

Paper III

Abbreviations

NO – nitric oxide; NOS – nitric Oxide Synthase; NADPH – nicotinamide dinucleotide phosphate; FAD – flavin adenine dinucleotide; FMN – flavin mononucleotide; CaM - calmodulin; BH₄ – tetrahydrobiopterin; NHA – N-hydroxy-L-arginine; Arg – Arginine, L-NAME - Ñ⁶-nitro-L-arginine methyl ester
Abstract
The nitric oxide synthases (NOS) are hemoproteins with a cytochrome P450-like active site that catalyze the oxidation of arginine to nitric oxide and citrulline. Different isoforms of this enzyme has been discovered: eNOS, iNOS, nNOS and mtNOS. However, only first three were shown to be genetically different. This paper contains a brief comparison of these isoform and discussion of their catalytical mechanism. Second part of the paper specifically focuses on NOS III. Structural features, different levels of regulation and biological significance of this enzyme is discussed.

Introduction
Nitric Oxide Synthases are the main mammalian enzymes that produce nitric oxide. These enzymes were shown to catalyze the following reaction [1].

\[
\begin{align*}
&\text{L-arginine} & &\stackrel{\text{NADPH}}{\longrightarrow} & &\text{N}^\text{\mu}\text{hydroxy-L-arginine} & &\stackrel{1/2\text{NADPH}}{\longrightarrow} & &\text{L-citrulline} \\
&\text{O}_2 & & & &\text{O}_2 & & & &\text{N=O}
\end{align*}
\] (1)

Traditionally, three isoforms of NOS were identified in mammalian systems: NOS-I, NOS-II and NOS-III. They are encoded by different genes and have different tissue distribution and regulation. Recently fourth, mitochondrial isoform has been identified [36]. However this isoform was shown to be a subtype
of nNOS [36]. This paper will focus only on three “classic” isoforms. The main features of these isoforms are summarized in Table 1.

Table 1.

<table>
<thead>
<tr>
<th>Isoform</th>
<th>NOS I (nNOS)</th>
<th>NOS II (iNOS)</th>
<th>NOS III (eNOS)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cellular localization</td>
<td>Cytosolic</td>
<td>Cytosolic</td>
<td>Membrane bound</td>
</tr>
<tr>
<td>Tissue distribution</td>
<td>Nervous system, skeletal muscles</td>
<td>Ubiquitous</td>
<td>Vascular endothelium, airway epithelium</td>
</tr>
<tr>
<td>Regulation</td>
<td>Ca$^{2+}$/CaM</td>
<td>Cytokine inducible; Ca$^{2+}$ independent</td>
<td>Ca$^{2+}$/CaM</td>
</tr>
<tr>
<td>Expression</td>
<td>Constitutive</td>
<td>Inducible</td>
<td>Constitutive</td>
</tr>
<tr>
<td>Gene structure</td>
<td>29 exons, 28 introns</td>
<td>26 exons, 25 introns</td>
<td>26 exons, 25 introns</td>
</tr>
<tr>
<td>Chromosomal location</td>
<td>12q24.2-12q24.3 of chromosome 12</td>
<td>17cen-q11.2 of chromosome 17</td>
<td>7q35-7q36 of chromosome 7</td>
</tr>
<tr>
<td>References</td>
<td>[17], [18]</td>
<td>[19], [20]</td>
<td>[22], [23]</td>
</tr>
</tbody>
</table>

Structure of NOS

NOS is a very complex enzyme that contains several cofactors and heme in the active site. Active NOS has a dimeric form (Fig 1).

![Fig 1. NOS dimer [Crane BR 1998]](image)

![Fig 2. Domain structure of NOS dimer [online sources]](image)

Each monomer has three domains: reductase domain, calmodulin binding domain and oxygenase domain (Fig 2, Fig 3). Reductase domain consists of two subunits, one that binds NADPH and FAD and the other that binds to FMN [24]. NADPH acts as a two electron donor. FAD and FMN serve as an electron storage pool and transfer agent. Ca$^{2+}$/Calmodulin binding domain is very small (approximately
30 aminoacids). Oxygenase domain contains heme group, substrate binding site and binding site for tetrahydrobiopterin. It was shown that dimer interface contains a zinc tetrahiolate center, located at the bottom of the dimer interface. The zinc ion is tetrahedrally coordinated to two cysteins from each subunit. Structure of some cofactors for NOS is shown on figure 3.

Fig. 3 Structure of cofactors for NOS [online sources]

**Catalytical mechanism of NOS**

NOS catalyzes two sequential, mechanically distinct, heme based reactions. The first step is the hydroxylation of the amide nitrogen atom of arginine. The second step is conversion of NHA to citrulline and NO. NADPH serves as an electron donor for both reactions.

Upon binding of Ca^{2+}/calmodulin, FAD transfers reducing equivalents from NADPH to FMN, which then reduces heme in oxygenase domain of opposite monomer (Fig. 4). The ferrous form of the heme binds oxygen to form stable oxy complex (Fig 5). Dissociation of this species is a source of superoxide anion in uncoupled NOS. The feroxy complex is then protonated and the oxygen – oxygen bond breaks to form a very active intermediate, that performs the two electron oxidation of arginine to NHA. Second oxidation reaction involves formation of ferric-peroxy intermediate that catalyses this reaction. Ferric iron is reduced to ferrous and oxygen binds.

Fig. 4. Redox potential and direction of electron flow in nNOS
This form of the enzyme then reacts directly with NHA to form an NHA radical and haem-peroxy complex. The NHA radical and the peroxy complex then react with each other in a “radical rebound” mechanism to generate citrulline and NO and regenerate the ferric haem iron [24].

Fig 5. Catalytical mechanism of NOS [Boga et al 1998]

Endothelial NOS

Endothelial NOS is the main source of NO in vasculature. Deregulation of eNOS is involved in pathogenesis of many cardiovascular diseases: atherosclerosis, hypertension, diabetes, hypercholesterolemia, hyperhomocysteinemia etc [24].

The eNOS knockout mouse (eNOS-/-) have the following phenotype: hypertension, poor vasorelaxing activity, increased neo-intimal proliferation and an increased contractile response to β-adrenergic agonists. Furthermore, it has been described that these animals have developmental growth problems, abnormal aortic valves, and limb abnormalities. These mice also exhibit impaired wound-healing capacity and a poor response to growth factor-stimulated angiogenesis. ENOS -/-mice also have impaired endothelium-dependent vasodilation in the pulmonary circulation [24].

Three different polymorphic variations in the human eNOS gene have been identified. Two single nucleotide substitutions have been identified within the introns, one in intron 18, Ala27Cys, and one in intron 23, Gly10Thr. Some variable repeats have also been located in introns 4, 13, and 23. Although a
normal functional enzyme is formed, the polymorphisms could lead to altered transcription and/or processing rates, thereby interfering with normal enzyme function. Individuals with a polymorphism in intron 13 have a higher risk of coronary artery disease [24]

The endothelial nitric oxide synthase (eNOS) is a dimer consisting of two identical monomers of 134 kD. The gene encoding for the eNOS monomer is located on chromosome 7q35-36 and contains 26 exons, spanning 21 kb. Domain structure of eNOS is shown on the Fig 5.

The eNOS enzyme is only fully functional in a dimeric form. Dimerization of eNOS starts with the binding of haem without haem, the eNOS enzyme exists only as a monomer. The binding of haem and the formation of a dimer make it possible for tetrahydrobiopterin to bind to the eNOS dimer, which leads
to the formation of a stable dimer. Stabilization of the dimer is also dependent on zinc ions, which maintain the integrity of the BH₄ binding site. The functional activity of the eNOS dimer is dependent on the number of BH₄ molecules bound. An eNOS dimer without BH₄ is capable of producing O₂⁻; the binding of one BH₄ molecule results in an eNOS dimer capable of producing both NO and O₂⁻. High levels of BH₄ result in a saturated dimer, which acts purely as an NO synthase [24].

It is thought that most eNOS is located in the caveolae, where it is bound to caveolin, a resident coat protein. The caveolin binding leads to inhibition of eNOS activity by interfering with the CaM binding and electron transfer to the haem subunit. A rising intracellular level of free Ca²⁺ causes the formation of Ca²⁺/CaM complexes, resulting in the binding of the enzyme and consequently the dissociation of caveolin. The eNOS enzyme is now activated and remains so until intracellular Ca²⁺ levels drop and the Ca²⁺/CaM complex is subsequently replaced by caveolin. The activated eNOS enzyme is productive as long as the substrates L-arginine, oxygen, and NAPDH are present. Altered lipid composition in the caveolae can displace the eNOS enzyme, thereby altering the eNOS activation process.

No specific inhibitors for eNOS are available so far. The most often used inhibitor for all isoforms of NOS is L-NAME.

**Conclusions**

It is difficult to underestimate significance of endothelial NOS. This enzyme is the major source of NO in vasculature. It is one of the most complex enzymes ever known. Activity of eNOS could be regulated on different levels. Impairment of eNOS function is involved in pathogenesis of many diseases. Studying eNOS could have a lot of therapeutic implications. Endothelial NOS gene therapy could be used a potent therapeutic tool in the future.
References


